Effect of nanocurcumin in heart failure

Phase 2

Recruiting

• Conditions: heart failure reduced EF.; Systolic (congestive) heart failure; I50.2

• Registration Number: IRCT20221007056110N1
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with reduced EF heart failure
Signing an informed consent form

Exclusion Criteria

No history of rheumatologic disease
No active infection
No acute kidney injury

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin 6. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: Laboratory tests.;NT-proBNP. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: Laboratory tests.

Secondary Outcome Measures

Name	Time	Method
Serum creatinine. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.;WBC count. Timepoint: En At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.;ALT. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.;AST. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.